<DOC>
	<DOC>NCT01479127</DOC>
	<brief_summary>To explore the safety, tolerability, pharmacokinetics and efficacy of ABT-SLV187 in advanced Parkinson's disease (PD) patients with severe motor complications. The complications of medical devices for the naso-jejunum (NJ) infusion system of ABT-SLV187 will also be investigated.</brief_summary>
	<brief_title>Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa, levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Silicon</mesh_term>
	<criteria>Idiopathic PD according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank criteria PD stage corresponds to 4 or 5 in the 'off' state according to the modified Hoehn &amp; Yahr (H &amp; Y) classification of disease severity Levodoparesponsive subjects demonstrate some identifiable 'ON response' established by observation by Investigator and demonstrate severe motor fluctuations in spite of individually optimized treatment and where therapy options are indicated Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists such as secondary parkinsonism Undergone surgery for the treatment of PD Contraindications to levodopa Subjects with any neurological deficit that may interfere with the study assessments</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Levodopa-carbidopa intestinal gel</keyword>
	<keyword>Advanced Parkinson's disease</keyword>
	<keyword>Severe motor fluctuations</keyword>
	<keyword>Dyskinesia</keyword>
</DOC>